Maximizing statistical power in group-randomized vaccine trials

Epidemiology and Infection

Volumn 133, Issue 6, 2005, Pages 993-1008

  Riggs, T ^a   Koopman, J S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY DETECTION; ARTICLE; BACTERIAL TRANSMISSION; COMPARATIVE STUDY; COMPARTMENT MODEL; DRUG RESEARCH; ENDEMIC DISEASE; HAEMOPHILUS INFLUENZAE; IMMUNE STATUS; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; MATHEMATICAL COMPUTING; NONHUMAN; PREVALENCE; PROBABILITY; SEROLOGY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; STOCHASTIC MODEL;

HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS;

EID: 28244481518     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S095026880500436X     Document Type: Article

References (17)

1. Hayes RJ, Alexander NDE, Bennett S, Cousens SN. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Statist Meth Med Res 2000; 9: 95-116.
2. Simon CP, Koopman JS. Infection transmission dynamics and vaccination program effectiveness as a function of vaccine effects in individuals. In: Castillo-Chavez C, Blower S., van den Driessche P, Kirschner D, Yakubu AA, eds. Mathematical approaches for emerging and reemerging infectious diseases, vol. 126. New York: Springer, 2002: 143-157.
3. Donner A, Klar N. Methods for comparing event rates in intervention studies when the unit of allocation is a cluster. Am J Epidemiol 1994; 140: 279-289.
4. Riggs TW, Koopman JS. A Stochastic model of vaccine trials for endemic infections using group randomization. Epidemiol Infect 2004; 132: 1-12.
5. Ross SM. Stochastic processes. New York: John Wiley & Sons, Inc., 1996.
6. Mode CJ, Sleeman CK. Stochastic processes in epidemiology: HIV/AIDS, other infectious diseases and computers. New Jersey: World Scientific Publishing Co., River Edge, 2000.
7. Macey R, Oster G, Zahnley T. Berkeley Madonna (v. 8.0). University of California, Berkeley, CA, 2000.
8. Lamphear BP, Byrd RS, Auinger P, Hall CB. Increasing prevalence of recurrent otitis media among children in the United States. Pediatrics 1997; 99: E1.
9. Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol Infect 2004; 132: 433-441.
10. Principi N, Marchisio P, Schito GC, Mannelli S. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy children. Ascanius Project Collaborative Group. Pediatr Infect Dis J 1999; 18: 517-523.
11. Vernacchio L, Lesko SM, Vezina RM, et al. Racial/ethnic disparities in the diagnosis of otitis media in children. Int J Pediatric Otorhinolaryngol 2004; 68: 795-804.
12. Huang SS, Finkelstein JA, Rifas-Shiman SL, Kleinman K, Platt R. Community-level predictors of pneumococcal carriage and resistance in young children. Am J Epidemiol 2004; 159: 645-654.
13. Longini IM, Sagatelian K, Rida WN, Halloran ME. Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. Stat Med 1998; 17: 1121-1136.
14. Smith PG, Rodrigues LC, Fine PE. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984; 13: 87-93.
15. Halloran ME, Longini Jr. IM. Using validation sets for outcomes and exposure to infection in vaccine field studies. Am J Epidemiol 2001; 154: 391-398.
16. Haber M, Orenstein WA, Halloran ME, Longini Jr IM. The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak. Am J Epidemiol 1995; 141: 980-990.
17. Murray DM (ed.). Design and analysis of group-randomized trials. New York: Oxford University Press, 1998: 355-365.